Security
Pasithea Therapeutics Corp. Common Stock · KTTA
KTTANASDAQCommon stockCurrentCIK 1841330Updated Oct 6, 2026
KTTA price & chart
Loading TradingView…
NASDAQ:KTTA on TradingView ↗About the company
Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in patients with advanced cancer (NCT06299839), and a Phase 1/1b clinical trial in patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas with symptomatic and inoperable, incompletely resected, or recurrent PN (NCT06961565).
In the news
No coverage from other publishers is available.
Recent filings
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07, 9.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01
10-Q filing
SCHEDULE 13G/A - filed by Vivo Opportunity Fund Holdings, L.P. regarding Pasithea Therapeutics Corp.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 13,630,664Source | 18,637,434Source | 51,709,945Source | 17,009,142Source | 17,663,384Source | 56,354,901Source | 14,658,982Source | 22,408,099Source | 60,240,070Source | 16,064,719Source | 26,116,858Source | 45,180,089Source |
| Property, Plant and Equipment, NetUSD | — | 127,060Source | — | 113,564Source | 131,776Source | — | 117,522Source | 136,491Source | — | 122,343Source | 141,208Source | 378,783Source |
| GoodwillUSD | 1,262,911Source | 1,262,911Source | — | 1,262,911Source | 1,262,911Source | — | 1,262,911Source | 1,262,911Source | — | 1,262,911Source | 1,262,911Source | 1,262,911Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 6,838,527Source | 7,468,691Source | — | 6,996,068Source | 7,626,232Source | — | 7,153,609Source | 7,783,773Source | 2,900,000Source | 7,311,150Source | 7,941,314Source | 8,587,239Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,122,953Source | 9,361,169Source | 45,663,782Source | 7,217,052Source | 7,967,569Source | 50,400,377Source | 5,341,278Source | 12,009,347Source | 55,158,939Source | 6,922,729Source | 16,331,052Source | 33,146,895Source |
| Assets, CurrentUSD | 5,529,226Source | 9,778,772Source | 48,244,041Source | 8,636,599Source | 8,642,465Source | 52,731,456Source | 6,124,940Source | 13,192,898Source | 56,459,084Source | 7,368,315Source | 16,692,154Source | 34,076,693Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | 32,026Source | — | — | 79,271Source | 874,463Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 1,423,982Source | 823,975Source | 1,870,258Source | 1,830,697Source | 1,488,124Source | 1,542,451Source | 1,680,199Source | 2,524,630Source | 5,020,832Source | 1,282,043Source | 2,718,406Source | 2,681,841Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 743Source | 104Source | 3,341Source | 743Source | 104Source | 2,494Source | 270Source | 104Source | 2,309Source | 139Source | 104Source | 17,987Source |
| Additional Paid in CapitalUSD | 72,087,231Source | 64,253,789Source | 127,980,571Source | 72,034,244Source | 59,228,967Source | 127,643,001Source | 66,124,529Source | 59,068,015Source | 125,208,624Source | 64,372,486Source | 58,721,538Source | 61,837,802Source |
| Retained Earnings (Accumulated Deficit)USD | -59,899,593Source | -46,405,117Source | -78,153,795Source | -56,862,173Source | -43,045,627Source | -72,879,943Source | -53,146,016Source | -39,179,378Source | -70,010,461Source | -49,582,778Source | -35,318,538Source | -19,356,880Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 18,301Source | -35,317Source | 9,570Source | 5,631Source | -8,184Source | 46,898Source | — | -5,272Source | 18,766Source | -7,171Source | -4,652Source | -661Source |
| Stockholders' Equity Attributable to ParentUSD | 12,206,682Source | 17,813,459Source | 49,839,687Source | 15,178,445Source | 16,175,260Source | 54,812,450Source | 12,978,783Source | 19,883,469Source | 55,219,238Source | 14,782,676Source | 23,398,452Source | 42,498,248Source |
| Liabilities and EquityUSD | 13,630,664Source | 18,637,434Source | 51,709,945Source | 17,009,142Source | 17,663,384Source | 56,354,901Source | 14,658,982Source | 22,408,099Source | 60,240,070Source | 16,064,719Source | 26,116,858Source | 45,180,089Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 1,377,111Source | 660,397Source | 1,837,917Source | 1,736,956Source | 1,394,852Source | 1,489,485Source | 1,594,894Source | 2,466,980Source | 4,973,961Source | 1,119,871Source | 2,634,040Source | 1,877,634Source |
| Operating Lease, Liability, CurrentUSD | — | — | — | — | — | — | — | 32,989Source | — | — | 81,680Source | 263,291Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 663,596Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 139,182Source | 98,558Source | 297,467Source | 773,693Source | 592,269Source | 552,823Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -4,787,220Source | -3,055,757Source | -15,211,490Source | — | — | -14,561,921Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | — | — | -77,060Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | 11,000Source | — | — | -2,061,546Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 34,301Source | 374,889Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 3,726,416Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 750Source | 1,474,306Source | 63,518,800Source | — | — | -3,206,244Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -4,758,338Source | -1,581,451Source | 48,337,076Source | -9,408,323Source | -16,756,812Source | -19,819,811Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,223,552Source | 9,361,169Source | 45,765,099Source | 7,217,052Source | 50,501,467Source | 5,341,278Source | 55,259,805Source | 6,922,729Source | 16,331,052Source | 33,146,895Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 13,212Source | 7,892Source | 13,212Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 28,132Source | — | 18,766Source | -2,519Source | — | — |
| Additional Financial Items | ||||||||||||
| AmortizationUSD | — | — | — | — | — | — | 157,541Source | 157,541Source | 630,164Source | 630,164Source | 630,164Source | — |
| Share-based Payment Arrangement, ExpenseUSD | — | — | — | 121,000Source | 329,000Source | 58,000Source | 138,000Source | 97,000Source | — | — | 72,000Source | — |
| DepreciationUSD | — | — | — | — | — | — | — | 4,821Source | 32,421Source | 18,865Source | 18,290Source | 31,520Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -26,250Source | — | -29,792Source | 29,290Source | -9,491Source | -7,171Source | 30,376Source | — | — | — |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | — | 65,048Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | 102,000Source | — | — | — | — | — | 102,000Source | — | -65,048Source | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | -1,016,941Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 44,723Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | — | — | — | — | — | — | — | — | — | — | 65,048Source | — |
| General and Administrative ExpenseUSD | — | — | 1,752,262Source | 1,423,228Source | 2,027,664Source | 1,662,223Source | 1,934,324Source | 1,950,328Source | 12,876,175Source | — | — | — |
| GoodwillUSD | — | — | 1,262,911Source | 1,262,911Source | — | 1,262,911Source | — | 1,262,911Source | — | 1,262,911Source | 1,262,911Source | 1,262,911Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 1.3Source | — | — | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | 2.9Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -2,999,834Source | — | — | — | — | — | -13,904,584Source | -15,507,748Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -453,910Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,037,420Source | -2,999,834Source | -5,273,852Source | -3,716,157Source | -2,869,482Source | -3,563,238Source | -20,427,683Source | -13,904,584Source | -15,961,658Source | -13,936,452Source |
| Nonoperating Income (Expense)USD | — | — | 72,635Source | 4,770Source | 439,430Source | 94,742Source | 2,007,162Source | 116,941Source | 429,612Source | 345,378Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | 17,531Source | — | — | — | — | — | 156,041Source | 243,230Source | 244,004Source |
| Other Nonoperating Income (Expense)USD | — | — | 7,000Source | — | — | 7,000Source | — | 7,000Source | 7,000Source | — | 471,613Source | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | 179,310Source | 448,279Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | 1,300,000Source | — | 1,652,745Source | 2,078,348Source | — | — | — |
| Depreciation and amortization | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 486,559Source |
| Cost of RevenueUSD | — | — | — | — | — | — | — | — | — | — | — | 113,195Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | — | 7,051,468Source | 7,878,596Source | 12,524,258Source |
| Operating Income (Loss)USD | — | — | -3,110,055Source | -3,004,604Source | -5,713,282Source | -3,810,899Source | -4,876,644Source | -3,680,179Source | -20,857,295Source | -14,249,962Source | -15,979,361Source | -14,816,321Source |
| Other Nonoperating Income (Expense)USD | — | — | 7,000Source | — | — | 7,000Source | — | 7,000Source | 7,000Source | — | 471,613Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,037,420Source | -2,999,834Source | -5,273,852Source | -3,716,157Source | -2,869,482Source | -3,563,238Source | -20,427,683Source | -13,904,584Source | -15,507,748Source | -13,936,452Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,037,420Source | -2,999,834Source | -5,273,852Source | -3,716,157Source | -2,869,482Source | -3,563,238Source | -20,427,683Source | -13,904,584Source | -15,961,658Source | -13,936,452Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.41Source | -2.87Source | -0.16Source | -0.66Source | -0.12Source | -1.61Source | -2.91Source | — | -0.42Source | -0.55Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.41Source | -2.87Source | -0.16Source | -0.66Source | -0.12Source | -1.61Source | -2.91Source | — | -0.42Source | -0.53Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 7,443,577Source | 1,044,144Source | 32,100,063Source | 5,641,251Source | 24,337,812Source | 2,211,207Source | 7,031,050Source | 1,096,082Source | 1,226,600Source | 25,251,756Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 7,443,577Source | 1,044,144Source | 32,100,063Source | 5,641,251Source | 24,337,812Source | 2,211,207Source | 7,031,050Source | 1,096,082Source | 1,226,600Source | 25,251,756Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 697,121Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | -26,250Source | — | -29,792Source | 29,290Source | -9,491Source | -7,171Source | 30,376Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | — | — | — | — | — | — | — | — | -1,016,941Source |
| General and Administrative ExpenseUSD | — | — | 1,752,262Source | 1,423,228Source | 2,027,664Source | 1,662,223Source | 1,934,324Source | 1,950,328Source | 12,876,175Source | — | — | — |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 1.3Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | -2,999,834Source | — | — | — | — | — | -13,904,584Source | -15,507,748Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | — | -2.87Source | — | — | — | — | — | -12.69Source | -12.64Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | — | — | -2.87Source | — | — | — | — | — | -12.69Source | -12.64Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | — | — | -453,910Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 102Source |
| Nonoperating Income (Expense)USD | — | — | 72,635Source | 4,770Source | 439,430Source | 94,742Source | 2,007,162Source | 116,941Source | 429,612Source | 345,378Source | — | — |
| Operating Lease, ExpenseUSD | — | — | — | 17,531Source | — | — | — | — | — | 156,041Source | 243,230Source | 244,004Source |
| Other ExpensesUSD | — | — | — | — | — | — | — | — | — | — | — | 311,000Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | 655Source | 700Source | — | — | — |
| Other IncomeUSD | — | — | — | — | — | — | — | — | — | — | — | 879,869Source |
| Research and Development ExpenseUSD | — | — | 1,357,793Source | 1,581,376Source | 3,685,618Source | 2,148,676Source | 2,942,320Source | 1,729,851Source | 7,981,120Source | 7,198,494Source | 8,100,765Source | 2,665,427Source |
| Depreciation, Depletion and Amortization, Nonproduction | — | — | —Source | —Source | — | — | — | — | — | — | — | — |
| Foreign Currency Transaction Gain (Loss), Realized | — | — | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-271010
Filing attachments
ea028886401ex99-1.htm · 8-K · 2026-05-04
EX-99.1 3 ea028886401ex99-1.htm PRESS RELEASE DATED MAY 4, 2026 Exhibit 99.1 Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph. D. as Chief Medical Officer MIAMI, FL., May 4, 2026 (GLOBE NEWSWIRE) - Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Kartik Krishnan, M.D., Ph. D. as Chief Medical Officer (CMO…
Read attachment ↗